A new drug could let those with severe food allergies breathe a sigh of relief. Xolair, or omalizumab, was granted priority review by the Food and Drug Administration on Tuesday for its use in ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted, under ...
ATLANTA - If you have to be vigilant about what you eat, and keep an EpiPen close, Dr. Tom Chacko of Chacko Allergy, Asthma and Sinus Center, says the newly FDA-authorized allergy medication, Xolair, ...
WILL TOTALLY CHANGE. A 17 YEAR OLD NICO DIAZ HAS SPENT HIS WHOLE LIFE WORRYING ABOUT BEING EXPOSED TO PEANUTS, CASHEW AND PISTACHIOS. I WOULD STOP BREATHING, UM, AND THEN I WOULD GET HIVES ALL OVER ...
CHICAGO (WLS) -- After the FDA approved a medication called Xolair to help lessen the severity of an accidental allergic reaction in people who are allergic to multiple foods, sufferers say they're ...
– Results were featured as late-breakers at the 2025 AAAAI Annual Meeting – – Xolair is the only U.S. FDA-approved medicine to reduce allergic reactions in children and adults with one or more food ...
This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. A medication used to treat asthma can now be ...
Stage 1 patients were randomized to receive placebo or Xolair injections either every two weeks or every four weeks for 16 to 20 weeks. The Xolair dose and dosing interval were determined by total ...
A new treatment appears to reduce food allergies in children and teens, according to interim clinical trial results. A lab-made monoclonal antibody called omalizumab (Xolair) significantly increased ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved the ...
If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposure Interim analysis results from first-of-its-kind phase III OUtMATCH study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback